Effect of metabolic syndrome and its components on the risk and prognosis of cervical cancer: A literature review.
Cervical cancer
Human papillomavirus
Metabolic syndrome
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
19
02
2024
revised:
13
06
2024
accepted:
17
06
2024
medline:
22
7
2024
pubmed:
22
7
2024
entrez:
22
7
2024
Statut:
epublish
Résumé
Despite the global implementation of preventive strategies against Human Papilloma Virus (HPV) infection, the incidence of invasive cervical cancer rose by nearly 1.3-fold, from 471,000 annual cases in 2000 to 604,000 cases in 2020. With over 340,000 deaths annually, cervical cancer is the fourth leading cause of cancer mortality in women globally. There is a need to understand other factors besides HPV such as metabolic syndrome (MetS) that potentially influence the onset and progression of cervical cancer. In this narrative review, we describe evidence showing that Metabolic syndrome (MetS) increases the risk for cervical cancer and worsens its prognosis. Combined screening for MetS and cervical cancer has potential to significantly reduce morbidity and mortality in women with cervical cancer.
Identifiants
pubmed: 39035032
doi: 10.1016/j.gore.2024.101438
pii: S2352-5789(24)00117-6
pmc: PMC11260376
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101438Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.